

Sibylle Loibl

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/712130/publications.pdf](https://exaly.com/author-pdf/712130/publications.pdf)

Version: 2025-02-01

318

PR articles

43,496

PR citations

4265

82

PR h-index

2258

197

g-index

379

documents

56260

doc citations

3034

95

h-index

58246

citing authors

#	ARTICLE	IF	CITATIONS
1	Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. <i>Lancet Regional Health - Europe</i> , The, 2025, 49, 101162.	7.0	3
2	Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. <i>New England Journal of Medicine</i> , 2025, 392, 1051-1064.	34.6	141
3	RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial. <i>Clinical Cancer Research</i> , 2025, 31, 808-814.	6.8	1
4	Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers. <i>Breast Cancer Research</i> , 2025, 27, .	4.8	4
5	TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2+ breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2025, 17, .	3.6	15
6	Dynamics of molecular heterogeneity in high-risk luminal breast cancer – From intrinsic to adaptive subtyping. <i>Cancer Cell</i> , 2025, 43, 232-247.e4.	33.0	12
7	Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD – Long-term Survival of the GeparOLA Study. <i>Clinical Cancer Research</i> , 2025, 31, 1596-1604.	6.8	3
8	CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. <i>Future Oncology</i> , 2025, 21, 795-806.	2.3	4
9	Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs. <i>Signal Transduction and Targeted Therapy</i> , 2025, 10, .	32.9	9
10	COGNITION-GUIDE – Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study. <i>Geburtshilfe Und Frauenheilkunde</i> , 2025, 85, 611-619.	0.6	1
11	Impact of the ONCOBIOME network in cancer microbiome research. <i>Nature Medicine</i> , 2025, 31, 1085-1098.	33.0	13
12	Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. <i>European Journal of Cancer</i> , 2025, 223, 115489.	4.9	4
13	Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification. <i>Npj Breast Cancer</i> , 2025, 11, .	6.4	0
14	Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2025, 393, 151-161.	34.6	41
15	The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. <i>ESMO Open</i> , 2025, 10, 105294.	5.3	1
16	Treatment of Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2025, 85, 677-693.	0.6	6
17	Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655). <i>European Journal of Surgical Oncology</i> , 2025, 51, 110253.	0.9	3
18	Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy. <i>Lancet, The</i> , 2025, 406, 603-614.	62.3	10

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes in high-risk HR+HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. <i>European Journal of Cancer</i> , 2024, 196, 113420.	4.9	3
20	Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immunology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2024, 262, 271-288.	4.9	14
21	Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference – a German expert perspective. <i>Strahlentherapie Und Onkologie</i> , 2024, 200, 461-467.	2.1	3
22	Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Breast</i> , 2024, 74, 103701.	2.3	5
23	Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. <i>Journal of Clinical Oncology</i> , 2024, 42, 1738-1744.	16.9	120
24	An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials. <i>Clinical Cancer Research</i> , 2024, 30, 3868-3880.	6.8	5
25	Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 3077-3082.	16.9	7
26	GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. <i>Npj Breast Cancer</i> , 2024, 10, .	6.4	1
27	Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPtello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2024, 25, 1231-1244.	27.4	32
28	Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. <i>Journal of Clinical Oncology</i> , 2024, 42, 3643-3651.	16.9	18
29	Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer. <i>Cancers</i> , 2024, 16, 3236.	3.8	7
30	On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research</i> , 2024, 26, .	4.8	3
31	Chemotherapy in older patients with early breast cancer. <i>Breast</i> , 2024, 78, 103821.	2.3	10
32	Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2024, 391, 1584-1596.	34.6	173
33	Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. <i>Cell Reports Medicine</i> , 2024, 5, 101825.	6.6	7
34	Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2023, 178, 70-81.	4.9	5
35	Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. <i>European Journal of Cancer</i> , 2023, 178, 23-33.	4.9	42
36	Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. <i>EClinicalMedicine</i> , 2023, 55, 101756.	8.2	70

#	ARTICLE	IF	CITATIONS
37	Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. <i>Journal of Clinical Oncology</i> , 2023, 41, 1370-1375.	16.9	50
38	Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2023, 9, 197.	14.4	166
39	AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2023, 20, 81-93.	0.0	1
40	Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. <i>Lancet</i> , 2023, 401, 1277-1292.	62.3	141
41	Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial. <i>Clinical Cancer Research</i> , 2023, 29, 2456-2465.	6.8	7
42	Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1569-1581.	6.8	37
43	Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>European Journal of Cancer</i> , 2023, 184, 48-59.	4.9	23
44	Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. <i>Cancer Cell</i> , 2023, 41, 585-601.e8.	33.0	173
45	Evolution of synchronous female bilateral breast cancers and response to treatment. <i>Nature Medicine</i> , 2023, 29, 646-655.	33.0	10
46	Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions. <i>Journal of the National Cancer Institute</i> , 2023, 115, 712-732.	4.6	29
47	The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy. <i>Breast Cancer Research</i> , 2023, 25, .	4.8	7
48	Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2023, 9, .	6.4	27
49	Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 2058-2070.	34.6	571
50	Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). <i>Breast Cancer Research and Treatment</i> , 2023, 201, 215-225.	2.4	8
51	Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial. <i>Clinical Cancer Research</i> , 2023, 29, 3384-3394.	6.8	6
52	Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. <i>Journal of Medical Genetics</i> , 2023, 60, 1186-1197.	3.8	3
53	The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. <i>EClinicalMedicine</i> , 2023, 61, 102085.	8.2	16
54	Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features. <i>Clinical Cancer Research</i> , 2023, 29, 3729-3743.	6.8	7

#	ARTICLE	IF	CITATIONS
55	Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immunology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2023, 260, 498-513.	4.9	43
56	Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immunology Biomarker Working Group on Breast Cancer. <i>Journal of Pathology</i> , 2023, 260, 514-532.	4.9	37
57	Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer. <i>JAMA Surgery</i> , 2023, 158, 1013.	8.8	20
58	Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). <i>Breast</i> , 2023, 72, 103575.	2.3	9
59	Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. <i>European Journal of Cancer</i> , 2023, 194, 113324.	4.9	5
60	Treatment of Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2023, 83, 1102-1116.	0.6	7
61	Behandlung des frÃ¼hen Mammakarzinoms - 18. Internationaler St.-Gallen-Konsens vor dem Hintergrund der aktuellen deutschen Therapieempfehlungen diskutiert. <i>Senologie - Zeitschrift FÃ¼r Mammadiagnostik Und -therapie</i> , 2023, 20, 241-256.	0.0	0
62	RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial. <i>Clinical Cancer Research</i> , 2023, 29, 4606-4612.	6.8	5
63	Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images. <i>European Journal of Cancer</i> , 2023, 195, 113390.	4.9	14
64	Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16). <i>Tj ETQq0 02rgBT /Overlock 10</i>	0.0	0
65	The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2023, 21, 89-105.	70.8	208
66	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	4.9	27
67	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.8	20
68	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392.	27.4	226
69	AGO-Empfehlungen zur operativen Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021. <i>Senologie - Zeitschrift FÃ¼r Mammadiagnostik Und -therapie</i> , 2022, 19, 56-64.	0.0	0
70	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	6.8	33
71	Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. <i>European Journal of Cancer</i> , 2022, 166, 185-201.	4.9	27
72	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	4.9	15

#	ARTICLE	IF	CITATIONS
73	mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. International Journal of Cancer, 2022, 150, 1357-1372.	4.3	11
74	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁺ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 2022, 28, 3433-3442.	6.8	175
75	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	4.6	5
76	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast, 2022, 64, 56-62.	2.3	5
77	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. European Journal of Cancer, 2022, 170, 54-63.	4.9	30
78	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer. JAMA Oncology, 2022, 8, 1010.	14.4	18
79	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 47-59.	4.5	11
80	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer ^{â€} phase 3 ASCENT study subanalysis. Npj Breast Cancer, 2022, 8, .	6.4	58
81	Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. Npj Precision Oncology, 2022, 6, .	6.5	26
82	Sacituzumab Govitecan: Past, Present and Future of a New Antibody ^{â€} Drug Conjugate and Future Horizon. Future Oncology, 2022, 18, 3199-3215.	2.3	32
83	Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 2022, 8, .	6.4	90
84	An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). JAMA Oncology, 2022, 8, 1676.	14.4	31
85	Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany. Geburtshilfe Und Frauenheilkunde, 2022, 82, 932-940.	0.6	19
86	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. Npj Breast Cancer, 2022, 8, .	6.4	36
87	AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. Geburtshilfe Und Frauenheilkunde, 2022, 82, 1031-1043.	0.6	20
88	Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Frontiers in Oncology, 2022, 12, .	2.6	3
89	Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer. JAMA Oncology, 2022, 8, 1668.	14.4	33
90	Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study. Breast, 2022, 66, 110-117.	2.3	5

#	ARTICLE	IF	CITATIONS
91	Schwangerschaft nach Krebs. Forum, 2022, , .	0.2	0
92	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 309-317.	4.6	93
93	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-â€“positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	6.8	8
94	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	2.3	195
95	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	27.4	72
96	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	6.8	42
97	Gene Expression-â€“Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research, 2021, 27, 2148-2158.	6.8	18
98	Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-â€“Comparison of Three Different GPA Prognostic Scores. Cancers, 2021, 13, 844.	3.8	9
99	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	27.4	229
100	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2021, 145, 44-52.	4.9	10
101	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	34.6	1,302
102	Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. JAMA Oncology, 2021, 7, 565.	14.4	41
103	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	13.3	133
104	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 1485-1505.	16.9	841
105	Breast cancer. Lancet, The, 2021, 397, 1750-1769.	62.3	1,354
106	Assessment of Ovarian Function in Phase-III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. Journal of the National Cancer Institute, 2021, 113, 1770-1778.	4.6	25
107	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	0.6	6
108	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-â€“The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	16.9	277

#	ARTICLE	IF	CITATIONS
109	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170.	4.9	73
110	Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie. <i>Onkologe</i> , 2021, 27, 820-830.	0.1	0
111	Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	34.6	1,387
112	Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens – Meinungsbild deutscher Expert*innen zur 17. Internationalen St.-Gallen-Konsensuskonferenz. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, 163-181.	0.0	1
113	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	25.1	149
114	Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2021, 152, 193-203.	4.9	31
115	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 15-23.	2.4	7
116	Utility of the CPS+ÆG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 153, 203-212.	4.9	14
117	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	27.4	452
118	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	27.4	281
119	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	4.9	16
120	A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer. <i>Future Oncology</i> , 2021, 17, 3911-3924.	2.3	12
121	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1291.	14.4	39
122	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	10.0	662
123	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). <i>European Journal of Cancer</i> , 2021, 156, 138-148.	4.9	16
124	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1112-1120.	0.6	23
125	THE ALPESIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC). <i>Breast</i> , 2021, 59, S49.	2.3	0
126	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. <i>Clinical Epigenetics</i> , 2021, 13, .	3.9	5

#	ARTICLE	IF	CITATIONS
127	AGO Algorithms for the Treatment of Breast Cancer: Update 2021. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1101-1111.	0.6	9
128	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. <i>Npj Breast Cancer</i> , 2021, 7, .	6.4	27
129	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, .	6.4	214
130	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncol</i> , 2020, 59, 75-81.	1.8	13
131	Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. <i>European Journal of Surgical Oncology</i> , 2020, 46, 223-228.	0.9	10
132	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>JAMA Surgery</i> , 2020, 155, e195410.	8.8	127
133	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 266-276.	4.3	20
134	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	4.0	22
135	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet</i> , 2020, 395, 117-122.	62.3	197
136	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	34.6	1,117
137	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020, 12, 2787.	3.8	18
138	Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. , 2020, 8, e001261.		26
139	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBC 84 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, .	4.0	34
140	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. <i>PLoS ONE</i> , 2020, 15, e0238021.	2.3	11
141	Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1229-1236.	0.6	5
142	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, .	6.4	19
143	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, .	6.4	138
144	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, .	6.4	165

#	ARTICLE	IF	CITATIONS
145	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	16.9	471
146	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>Oncolimmunology</i> , 2020, 9, .	5.4	30
147	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020, 130, 92-101.	4.9	37
148	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GepearQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1896-1904.	6.8	13
149	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.9	190
150	Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2020, 126, 3132-3139.	4.0	20
151	Lucitanib for the Treatment of HR+/HER2 ⁺ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	6.8	54
152	Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 683-693.	1.5	39
153	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 689-696.	3.3	46
154	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	2.3	39
155	Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. <i>Breast Cancer</i> , 2019, 26, 826-834.	2.0	1
156	Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1110-1117.	0.6	2
157	Breast Cancer in Young and Premenopausal Women. <i>Annals of Oncology</i> , 2019, 30, vi67.	10.0	0
158	The Rise of Oncology Biosimilars: From Process to Promise. <i>Future Oncology</i> , 2019, 15, 3255-3265.	2.3	11
159	Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GepearQuinto Trial. <i>Cancers</i> , 2019, 11, 1186.	3.8	11
160	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019, 65, 1405-1413.	1.1	79
161	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the gepearquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	4.3	12
162	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.6	34

#	ARTICLE	IF	CITATIONS
163	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 557-568.	2.4	12
164	Breast cancer, placenta and pregnancy. <i>European Journal of Cancer</i> , 2019, 115, 68-78.	4.9	33
165	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	34.6	2,281
166	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. <i>Breast Cancer Research</i> , 2019, 21, .	4.8	16
167	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2257-2269.	16.9	180
168	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3986-3995.	6.8	41
169	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	5.5	62
170	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	62.3	347
171	Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. <i>British Journal of Cancer</i> , 2019, 121, 1009-1015.	5.5	19
172	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, .	4.8	33
173	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.5	989
174	Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. <i>British Journal of Cancer</i> , 2019, 120, 301-305.	5.5	36
175	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	2.7	34
176	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	4.9	101
177	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 617-628.	34.6	2,234
178	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	4.9	91
179	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 497-509.	27.4	677
180	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	4.6	253

#	ARTICLE	IF	CITATIONS
181	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , 2018, 24, 3358-3365.	6.8	17
182	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39.	27.4	956
183	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 40-50.	27.4	1,841
184	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	27.4	105
185	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patientâ€Level Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 1981-1990.	16.9	346
186	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1056-1088.	0.6	74
187	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 927-948.	0.6	70
188	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	34.6	1,087
189	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	25.1	559
190	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49.	2.3	87
191	Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 71-77.	9.6	77
192	Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. <i>Oncologist</i> , 2018, 23, 974-981.	3.4	19
193	Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). <i>Contemporary Clinical Trials</i> , 2018, 71, 194-198.	1.6	21
194	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018, 18, .	2.9	111
195	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	25.2	226
196	pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy â€A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. <i>Breast</i> , 2017, 32, 73-78.	2.3	7
197	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy â€Results from the multi-center SENTINA trial. <i>Breast</i> , 2017, 31, 202-207.	2.3	63
198	Efficacy and safety of nab-paclitaxel 125Âmg/m2 and nab-paclitaxel 150Âmg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). <i>Breast Cancer Research and Treatment</i> , 2017, 163, 495-506.	2.4	24

#	ARTICLE	IF	CITATIONS
199	HER2-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2415-2429.	62.3	970
200	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2403-2414.	62.3	190
201	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	37.9	1,398
202	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	25.2	394
203	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017, 85, 133-145.	4.9	95
204	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	14.4	344
205	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). <i>European Journal of Cancer</i> , 2017, 84, 1-8.	4.9	18
206	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 111-138.	2.3	715
207	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.3	613
208	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. <i>Clinical Cancer Research</i> , 2017, 23, 5384-5393.	6.8	103
209	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, .	6.4	12
210	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017, 22, 1028-1038.	3.4	130
211	Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years. <i>Modern Pathology</i> , 2017, 31, 607-615.	4.8	30
212	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2017, 167, 59-71.	2.4	42
213	Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 144, 343-358.	2.3	8
214	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immunology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	4.8	278
215	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5747-5754.	6.8	181
216	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2016, 22, 5238-5248.	6.8	56

#	ARTICLE	IF	CITATIONS
217	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	16.6	90
218	Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 444-455.	2.3	10
219	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2016, 53, 65-74.	4.9	64
220	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2675-2683.	6.8	46
221	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoâ€”GBC 69): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 345-356.	27.4	371
222	Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. <i>Cancer Treatment Reviews</i> , 2016, 43, 19-26.	9.6	54
223	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016, 26, 87-99.	2.3	149
224	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 470, 143-151.	2.9	2
225	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	4.3	34
226	Palbociclib in Hormone-Receptorâ€”Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	34.6	1,471
227	Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. <i>Current Breast Cancer Reports</i> , 2015, 7, 203-209.	0.8	3
228	Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 127-139.	2.4	104
229	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 377-387.	2.4	102
230	Breast Cancer Diagnosed During Pregnancy. <i>JAMA Oncology</i> , 2015, 1, 1145.	14.4	202
231	Dual Blockade with Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxaneâ€”Anthracycline Containing Chemotherapyâ€”DAFNE (GBC-70). <i>Clinical Cancer Research</i> , 2015, 21, 2924-2931.	6.8	39
232	Neoadjuvant treatment of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 85-91.	1.8	19
233	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, .	7.1	51
234	A randomized phase 2 study comparing EC or CMF versus nabâ€”paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to highâ€”risk early breast cancer (ICE IIâ€”GBC) Tj ETQq0 0.0 rgBT /Overlock 10		

#	ARTICLE	IF	CITATIONS
235	Classical pathology and mutational load of breast cancer – integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 225-238.	3.3	100
236	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , 2015, 113, 1565-1570.	5.5	98
237	Standardized Ki67 Diagnostics Using Automated Scoring – Clinical Validation in the GeparTrio Breast Cancer Study. <i>Clinical Cancer Research</i> , 2015, 21, 3651-3657.	6.8	94
238	Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. <i>International Journal of Cancer</i> , 2014, 134, 1725-1733.	4.3	46
239	Analysis of PIK3CA Mutations in Breast Cancer Subtypes. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 50-56.	1.0	54
240	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet</i> , The, 2014, 384, 164-172.	62.3	4,148
241	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 153-162.	2.4	105
242	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	2.3	151
243	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 61-68.	2.4	114
244	RANK expression as a prognostic and predictive marker in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 307-315.	2.4	64
245	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). <i>Annals of Surgical Oncology</i> , 2014, 21, 2517-2524.	2.3	26
246	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 747-756.	27.4	939
247	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 149, 141-149.	2.4	19
248	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2014, 22, 1118-1127.	2.3	91
249	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. <i>Pharmacoeconomics</i> , 2014, 33, 179-190.	3.6	24
250	HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. <i>Breast Cancer Research</i> , 2013, 15, .	4.8	63
251	Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 779-787.	2.4	23
252	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	10.0	3,287

#	ARTICLE	IF	CITATIONS
253	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	2.3	32
254	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1203-1212.	1.9	10
255	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab “ Results of the randomised GeparQuinto study (GBG 44). <i>European Journal of Cancer</i> , 2013, 49, 2284-2293.	4.9	80
256	Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1681-1689.	2.3	13
257	Update on neoadjuvant/preoperative therapy of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 66-73.	1.8	20
258	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4521-4531.	6.8	160
259	Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer “ A Substudy of the Neoadjuvant GeparQuinto Trial. <i>PLoS ONE</i> , 2013, 8, e79775.	2.3	199
260	Breast cancer in pregnancy. <i>Lancet, The</i> , 2012, 379, 570-579.	62.3	248
261	Treatment of breast cancer during pregnancy: an observational study. <i>Lancet Oncology, The</i> , 2012, 13, 887-896.	27.4	243
262	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology, The</i> , 2012, 13, e148-e160.	27.4	538
263	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2012, 13, 135-144.	27.4	440
264	Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. <i>Genome Medicine</i> , 2012, 4, .	9.6	96
265	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 299-309.	34.6	498
266	The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 3355-3377.	4.9	259
267	Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer“Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. <i>Journal of Proteome Research</i> , 2012, 11, 850-860.	3.4	72
268	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 136-150.	5.0	15
269	Neoadjuvant Clinical Trials for the Treatment of Primary Breast Cancer: The Experience of the German Study Groups. <i>Current Oncology Reports</i> , 2012, 14, 27-34.	4.2	4
270	Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e45826.	2.3	48

#	ARTICLE	IF	CITATIONS
271	Bevacizumab Treatment for Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 1684-1697.	3.4	34
272	Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 2273-2281.	4.9	171
273	Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. <i>Breast</i> , 2011, 20, S142-S145.	2.3	21
274	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 477-487.	2.4	197
275	Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. <i>Seminars in Immunopathology</i> , 2011, 33, 341-351.	8.1	22
276	Incorporating Agents that Target HER2 in the Neoadjuvant Setting. <i>Current Breast Cancer Reports</i> , 2011, 3, 190-196.	0.8	0
277	Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. <i>BMC Cancer</i> , 2011, 11, .	2.9	109
278	The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2141-2149.	1.1	7
279	Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. <i>Cancer Research</i> , 2011, 71, 3236-3245.	3.8	505
280	Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40). <i>Breast Cancer Research and Treatment</i> , 2011, 132, 863-870.	2.4	58
281	Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 437-445.	2.4	50
282	Effect of neoadjuvant anthracycline—taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 133-140.	2.4	261
283	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2634-2645.	6.8	484
284	Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2015-2023.	16.9	205
285	nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 515-523.	2.6	14
286	Breast cancer in pregnancy: Recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , 2010, 46, 3158-3168.	4.9	263
287	Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 105-113.	16.9	1,612
288	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , 2010, 125, 145-156.	2.4	249

#	ARTICLE	IF	CITATIONS
289	Comparison of pegfilgrastim on dayÂ2 vs. dayÂ4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Supportive Care in Cancer, 2010, 19, 1789-1795.	2.2	25
290	Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Research, 2009, 11, .	4.8	97
291	Neoadjuvant breast cancer therapy: the German experience. European Journal of Cancer, Supplement, 2008, 6, 4-9.	0.5	1
292	Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Research, 2008, 10, .	4.8	46
293	Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Research, 2008, 10, .	4.8	100
294	Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial. Journal of the National Cancer Institute, 2008, 100, 542-551.	4.6	279
295	Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study. Journal of the National Cancer Institute, 2008, 100, 552-562.	4.6	238
296	A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer â€“ GABG-IV B-93. European Journal of Cancer, 2007, 43, 2351-2358.	4.9	23
297	Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide. Supportive Cancer Therapy, 2006, 3, 103-109.	1.1	4
298	Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPAR DUO Trial. Annals of Surgical Oncology, 2006, 13, 1434-1442.	2.3	85
299	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Annals of Surgical Oncology, 2006, 13, 1702-1710.	2.3	395
300	Breast carcinoma during pregnancy. Cancer, 2006, 106, 237-246.	4.0	283
301	Use of goserelin in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2005, 5, 591-604.	2.5	15
302	Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells. Neoplasia, 2004, 6, 786-795.	7.0	122
303	EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. Journal of Cancer Research and Clinical Oncology, 2003, 129, 250-251.	2.3	4
304	Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. International Journal of Cancer, 2002, 101, 390-394.	4.3	19
305	Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer, 2002, 95, 1191-1198.	4.0	79
306	Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene, 2002, 21, 3162-3171.	6.5	154

#	ARTICLE	IF	CITATIONS
307	Title is missing!. , 2002, .		2
308	AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025. European Journal of Surgical Oncology, 0, 51, 110445.	0.9	2
309	Behandlung von Patientinnen mit frÃ¼hem Mammakarzinom. Senologie - Zeitschrift FÃ¼r Mammadiagnostik Und -therapie, 0, 22, 200-216.	0.0	0
310	Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clinical Cancer Research, 0, 31, 4903-4911.	6.8	1
311	Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Annals of Oncology, 0, 36, 1433-1446.	10.0	4
312	A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclibâ€™s Journey from Discovery to Approval and Whatâ€™s Next in CDK Inhibition in Breast Cancer. Targeted Oncology, 0, 20, 917-936.	3.2	0
313	Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study. Lancet Regional Health - Europe, The, 0, 59, 101471.	7.0	1
314	Molekulare Testungen zu therapeutischen Zwecken bei Brustkrebs â€“ Hilfe fÃ¼r die klinische Praxis. Geburtshilfe Und Frauenheilkunde, 0, 85, 1131-1136.	0.6	0
315	Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBC and AGO-B Study Group trials. Lancet Oncology, The, 0, 26, 1584-1597.	27.4	1
316	MedikamentÃ¶se Therapie des frÃ¼hen Mammakarzinoms. Die Onkologie, 0, 32, 100-109.	0.2	0
317	Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. Npj Breast Cancer, 0, 12, .	6.4	0
318	Palbociclib for Hormone-Receptorâ€Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 0, 394, 451-462.	34.6	0